Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15284859rdf:typepubmed:Citationlld:pubmed
pubmed-article:15284859lifeskim:mentionsumls-concept:C0019196lld:lifeskim
pubmed-article:15284859lifeskim:mentionsumls-concept:C0003451lld:lifeskim
pubmed-article:15284859lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:15284859lifeskim:mentionsumls-concept:C1367654lld:lifeskim
pubmed-article:15284859lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:15284859lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:15284859lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:15284859lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:15284859pubmed:issue10lld:pubmed
pubmed-article:15284859pubmed:dateCreated2004-9-28lld:pubmed
pubmed-article:15284859pubmed:abstractTextA link between chronic hepatitis C virus (HCV) infection and low-grade B-cell lymphomas has been suggested by epidemiological studies. Marginal zone lymphomas (MZLs) including splenic lymphomas with villous lymphocytes are among the most frequently reported subgroups in the setting of chronic HCV infection. In this study, we examined the effect of antiviral treatment in eight patients with HCV-associated MZL. We found that five out of eight patients have responded to interferon alpha and ribavirin. In some cases, hematologic responses were correlated to virologic responses. In addition, we report a case of large granular lymphocyte leukemia occurring in association with MZL and HCV, and responding to interferon and ribavirin. We suggest that there is an etiologic link between HCV and antigen-driven lymphoproliferative disorders.lld:pubmed
pubmed-article:15284859pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15284859pubmed:languageenglld:pubmed
pubmed-article:15284859pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15284859pubmed:citationSubsetIMlld:pubmed
pubmed-article:15284859pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15284859pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15284859pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15284859pubmed:statusMEDLINElld:pubmed
pubmed-article:15284859pubmed:monthOctlld:pubmed
pubmed-article:15284859pubmed:issn0887-6924lld:pubmed
pubmed-article:15284859pubmed:authorpubmed-author:ChristoforovB...lld:pubmed
pubmed-article:15284859pubmed:authorpubmed-author:TulliezMMlld:pubmed
pubmed-article:15284859pubmed:authorpubmed-author:ParkSSlld:pubmed
pubmed-article:15284859pubmed:authorpubmed-author:DreyfusFFlld:pubmed
pubmed-article:15284859pubmed:authorpubmed-author:CalmusYYlld:pubmed
pubmed-article:15284859pubmed:authorpubmed-author:BlanchePPlld:pubmed
pubmed-article:15284859pubmed:authorpubmed-author:SogniPPlld:pubmed
pubmed-article:15284859pubmed:authorpubmed-author:PodevinPPlld:pubmed
pubmed-article:15284859pubmed:authorpubmed-author:BouscaryDDlld:pubmed
pubmed-article:15284859pubmed:authorpubmed-author:RollotFFlld:pubmed
pubmed-article:15284859pubmed:authorpubmed-author:KelaidiCClld:pubmed
pubmed-article:15284859pubmed:issnTypePrintlld:pubmed
pubmed-article:15284859pubmed:volume18lld:pubmed
pubmed-article:15284859pubmed:ownerNLMlld:pubmed
pubmed-article:15284859pubmed:authorsCompleteYlld:pubmed
pubmed-article:15284859pubmed:pagination1711-6lld:pubmed
pubmed-article:15284859pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:15284859pubmed:meshHeadingpubmed-meshheading:15284859...lld:pubmed
pubmed-article:15284859pubmed:meshHeadingpubmed-meshheading:15284859...lld:pubmed
pubmed-article:15284859pubmed:meshHeadingpubmed-meshheading:15284859...lld:pubmed
pubmed-article:15284859pubmed:meshHeadingpubmed-meshheading:15284859...lld:pubmed
pubmed-article:15284859pubmed:meshHeadingpubmed-meshheading:15284859...lld:pubmed
pubmed-article:15284859pubmed:meshHeadingpubmed-meshheading:15284859...lld:pubmed
pubmed-article:15284859pubmed:meshHeadingpubmed-meshheading:15284859...lld:pubmed
pubmed-article:15284859pubmed:meshHeadingpubmed-meshheading:15284859...lld:pubmed
pubmed-article:15284859pubmed:meshHeadingpubmed-meshheading:15284859...lld:pubmed
pubmed-article:15284859pubmed:meshHeadingpubmed-meshheading:15284859...lld:pubmed
pubmed-article:15284859pubmed:meshHeadingpubmed-meshheading:15284859...lld:pubmed
pubmed-article:15284859pubmed:meshHeadingpubmed-meshheading:15284859...lld:pubmed
pubmed-article:15284859pubmed:meshHeadingpubmed-meshheading:15284859...lld:pubmed
pubmed-article:15284859pubmed:meshHeadingpubmed-meshheading:15284859...lld:pubmed
pubmed-article:15284859pubmed:meshHeadingpubmed-meshheading:15284859...lld:pubmed
pubmed-article:15284859pubmed:meshHeadingpubmed-meshheading:15284859...lld:pubmed
pubmed-article:15284859pubmed:year2004lld:pubmed
pubmed-article:15284859pubmed:articleTitleResponse to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas.lld:pubmed
pubmed-article:15284859pubmed:affiliation1Department of Hematology, Hôpital Cochin, Université Paris V, Assistance Publique Hôpitaux de Paris, Paris, France.lld:pubmed
pubmed-article:15284859pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15284859pubmed:publicationTypeCase Reportslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15284859lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15284859lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15284859lld:pubmed